日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study

伊扎隆单抗布伦吉特康治疗局部晚期或转移性非小细胞肺癌(伴有除经典 EGFR 突变以外的可靶向基因组改变):一项 Ib 期研究

Zhou, Huaqiang; Zhao, Hongyun; Hou, Xue; Wang, Yongsheng; He, Zhiyong; Li, Yongsheng; Ma, Yuxiang; Zhao, Yuanyuan; Huang, Yan; Chen, Likun; Xiao, Sa; Zhu, Hai; Zhu, Yi; Fang, Wenfeng; Zhang, Li; Yang, Yunpeng

Diverse genomic and transcriptomic heterogeneity in EGFR-mutant lung adenocarcinoma between exon 19 del and exon 21 L858R

EGFR突变型肺腺癌中,外显子19缺失突变和外显子21 L858R突变之间存在多种基因组和转录组异质性。

Yang, Yuwen; Qiao, Sitan; Sun, Dongchen; Zhang, Zhonghan; Zhao, Yuanyuan; Zhan, Jianhua; Huang, Yan; Zhao, Hongyun; Yang, Yunpeng; Wu, Kui; Zhou, Xinlan; Zhang, Lanjun; Long, Hao; Yang, Haoxian; Wang, Junye; Wang, Xin; Wen, Zhesheng; Zhang, Lin; Zhang, Li; Fang, Wenfeng; Zhao, Xin; Zhang, Yaxiong

Direct receptor competition gates RGL2 proteolysis for seed germination timing in Arabidopsis.

受体直接竞争控制拟南芥种子萌发时间的 RGL2 蛋白水解。

Nie Kaili, Jiang Juntao, Xie Changgen, Zhao Hongyun, Zheng Yuan

Synthesis of biochar-supported sulfidated nanoscale zero-valent iron and its application as a persulfate activator for remediation of crude oil-contaminated soil

合成生物炭负载硫化纳米零价铁及其作为过硫酸盐活化剂在原油污染土壤修复中的应用

Zheng, Jin; Zhai, Yong; Gao, Chunyang; Niu, Mengmeng; Li, Jufeng; Chen, Hongkun; Xu, Jun; Wang, Wenwen; Wu, Qian; Zhao, Hongyun; Nie, Ziqiu; Du, Xianyuan

Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial

HA121-28 在晚期实体瘤和 RET 融合阳性非小细胞肺癌患者中的安全性、药代动力学和疗效:一项多中心、开放标签、单臂 1/2 期试验

Ruan, Dan-Yun; Huang, Wen-Wen; Li, Yongsheng; Zhao, Yanqiu; Shi, Yehui; Jia, Yuming; Cang, Shundong; Zhang, Wei; Shi, Jianhua; Chen, Jun; Lin, Jie; Liu, Yunpeng; Xu, Jianming; Ouyang, Weiwei; Fang, Jian; Zhuang, Wu; Liu, Caigang; Bu, Qing; Li, Manxiang; Meng, Xiangjiao; Sun, Meili; Yang, Nong; Dong, Xiaorong; Pan, Yueyin; Li, Xingya; Qu, Xiujuan; Zhang, Tongmei; Yuan, Xianglin; Hu, Sheng; Guo, Wei; Li, Yalun; Li, Shengqing; Liu, Dongying; Song, Feixue; Tan, Liping; Yu, Yan; Yu, Xinmin; Zang, Aimin; Sun, Chang; Zhang, Qian; Zou, Kai; Dan, Mo; Xu, Rui-Hua; Zhao, Hongyun

A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.

针对晚期实体瘤的 B7H3 靶向抗体药物偶联物:一项 1/1b 期试验

Ma Yuxiang, Yang Yunpeng, Huang Yan, Fang Wenfeng, Xue Jinhui, Meng Xiangjiao, Fan Yun, Fu Siqing, Wu Lin, Zheng Yulong, Liu Jian, Liu Zhihua, Zhuang Wu, Rosen Seth, Qu Song, Li Bihui, Li Mingjun, Zhao Yanqiu, Yang Shujun, Ji Yinghua, Sommerhalder David, Luo Suxia, Yang Kunyu, Li Jingao, Lv Dongqing, Zhang Peng, Zhao Yuanyuan, Hong Shaodong, Zhang Yang, Zhao Shen, Chin Steve, Zhang Xian, Lian Wei, Cai Jiaqiang, Xue Tongtong, Zhang Li, Zhao Hongyun

Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study

对于EGFR突变型晚期非小细胞肺癌患者,在EGFR酪氨酸激酶抑制剂治疗失败后,采用Iparomlimab和tuvonralimab(QL1706)联合化疗和贝伐单抗治疗:DUBHE-L-201研究中第5组队列的最新结果

Zhang, Yaxiong; Huang, Yan; Yang, Yunpeng; Zhao, Yuanyuan; Zhao, Hongyun; Zhou, Ningning; Chen, Likun; Zhou, Ting; Chen, Gang; Zhao, Shen; Zhou, Huaqiang; Li, Hui; Kang, Xiaoyan; Zhang, Li; Fang, Wenfeng

The transcription factor MYB30 promotes iron homeostasis by maintaining the stability of the FIT transcription factor

转录因子MYB30通过维持FIT转录因子的稳定性来促进铁稳态。

Zhao, Hongyun; Jiang, Juntao; Shen, Mengai; Zhang, Yiyi; Zhang, Yamei; Liu, Huilin; Zhou, Huapeng; Zheng, Yuan

Phase I Clinical Trial of CVL218, a Novel PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors

新型PARP1/2抑制剂CVL218治疗晚期实体瘤患者的I期临床试验

Chen, Zihong; Chen, Gang; Ma, Yuxiang; Zhao, Hongyun; Zhan, Jianhua; Huang, Yan; Yang, Yunpeng; Zhao, Yuanyuan; Hong, Shaodong; Zhou, Ting; Fang, Wenfeng; Zhang, Li; Zhang, Yaxiong

Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.

Izalontamab (SI-B001) 是一种新型 EGFRxHER3 双特异性抗体,用于治疗局部晚期或转移性上皮肿瘤患者:首次人体 I/Ib 期研究的结果。

Xue Jinhui, Ma Yuxiang, Zhao Yuanyuan, Wang Yongsheng, Hong Wei, Huang Yan, Yang Yunpeng, Fang Wenfeng, Hong Shaodong, Zhang Yang, Liu Qianwen, Zhu Yi, Zhu Hai, Xiao Sa, Zhang Li, Zhao Hongyun